MBRX

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Moleculin Biotech Inc

NASDAQ | MBRX

0.49

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 23, 2025)

$22.11M

Market Cap

-

P/E Ratio

-3.74

EPS

$3.33

52 Week High

$0.25

52 Week Low

HEALTHCARE

Sector

MBRX Chart

Recent Chart
Price Action

MBRX Technicals

Tags:

MBRX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$126K
Total Revenue $0
Cost Of Revenue $126K
Costof Goods And Services Sold $126K
Operating Income -$27M
Selling General And Administrative $8.8M
Research And Development $18M
Operating Expenses $27M
Investment Income Net -
Net Interest Income $550K
Interest Income $550K
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $126K
Income Before Tax -$22M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$22M
Comprehensive Income Net Of Tax -
Ebit -$22M
Ebitda -$22M
Net Income -$22M

Revenue & Profitability

Earnings Performance

MBRX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $17M
Total Current Assets $5.2M
Cash And Cash Equivalents At Carrying Value $4.3M
Cash And Short Term Investments $4.3M
Inventory -
Current Net Receivables $20K
Total Non Current Assets $12M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $11M
Intangible Assets Excluding Goodwill $11M
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $896K
Other Non Current Assets -
Total Liabilities $11M
Total Current Liabilities $5.4M
Current Accounts Payable $2M
Deferred Revenue -
Current Debt -
Short Term Debt $240K
Total Non Current Liabilities $5.6M
Capital Lease Obligations $478K
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $478K
Other Current Liabilities $3.1M
Other Non Current Liabilities -
Total Shareholder Equity $6M
Treasury Stock -
Retained Earnings -$153M
Common Stock $3K
Common Stock Shares Outstanding $3.4M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$24M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $126K
Capital Expenditures $13K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$13K
Cashflow From Financing $4.6M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$22M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$126K
Total Revenue $0
Cost Of Revenue $126K
Costof Goods And Services Sold $126K
Operating Income -$27M
Selling General And Administrative $8.8M
Research And Development $18M
Operating Expenses $27M
Investment Income Net -
Net Interest Income $550K
Interest Income $550K
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $126K
Income Before Tax -$22M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$22M
Comprehensive Income Net Of Tax -
Ebit -$22M
Ebitda -$22M
Net Income -$22M

MBRX News

MBRX Profile

Moleculin Biotech Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company located in Houston, Texas, specializing in innovative therapies for cancer and viral infections. It is leveraging proprietary technology to advance a diverse pipeline of drug candidates designed to tackle highly resistant tumors and address significant unmet needs in oncology. With its commitment to scientific rigor and breakthrough treatments, Moleculin Biotech is well-positioned to make a substantial impact on the future of cancer care, significantly contributing to advancements in the field of oncology.

YYAI
-50.60%
$0.09
BYND
-20.67%
$2.84
SCNX
+354.94%
$2.60
YDKG
+5.58%
$0.07
F
-0.72%
$12.34
CGBS
-39.47%
$0.03
VHAI
0.00%
$0.00
RGTI
+9.80%
$39.59
AIRE
+38.18%
$0.98
RIG
+13.74%
$3.89
TSLA
+2.28%
$448.98
INTC
+3.35%
$38.15
BURU
-5.27%
$0.34
VTYX
+70.98%
$6.60
NOK
+11.17%
$6.17
QBTS
+13.81%
$31.06
NVDA
+1.04%
$182.16
T
-3.63%
$24.62
ADAP
-3.44%
$0.07
MSAI
+101.73%
$1.35
AAL
+5.62%
$12.77
BITF
+5.71%
$4.16
VIVK
+5.68%
$0.26
WTO
-7.04%
$0.06
IONZ
-14.59%
$3.98
AREB
+75.34%
$3.77
AXDX
-61.36%
$0.03
DNN
+0.36%
$2.73
IONQ
+7.06%
$59.37
PLUG
-1.36%
$2.88
ABEV
+0.45%
$2.21
SMCI
-8.72%
$47.92
QUBT
+7.19%
$15.94
TLRY
+2.06%
$1.48
VZ
-3.51%
$38.40
RGTZ
-20.27%
$14.90
GRAB
+1.77%
$5.72
SOFI
+3.27%
$28.08
RBNE
+7.87%
$1.37
BBD
+1.51%
$3.35
JOBY
+1.29%
$15.67
RF
-0.04%
$24.10
CAN
+3.22%
$1.76
ETHD
-3.17%
$3.97
ACHR
+0.46%
$10.91
QS
+7.95%
$14.66
RMBL
+60.50%
$3.21
SGBX
+29.82%
$2.96
AMD
+2.06%
$234.99
BTG
+0.38%
$5.23
ADD
-25.47%
$0.05
VLY
+4.24%
$10.56
ONDS
+4.74%
$7.06
GPUS
-0.28%
$0.38
PLTR
+2.84%
$180.48
LAES
+5.92%
$5.72
RXRX
-0.34%
$5.73
SRM
+53.27%
$10.30
CIFR
+7.10%
$17.25
PFE
-0.20%
$24.67
TNGX
-13.04%
$7.53
UUUU
-6.50%
$21.26
BTBT
+3.62%
$3.72
AAPL
+0.43%
$259.58
MARA
+0.36%
$19.22
AMC
-0.72%
$2.73
DVLT
+5.14%
$2.25
WBD
+3.50%
$21.25
AMZN
+1.44%
$221.09
IREN
+7.77%
$55.86
HPE
+0.43%
$23.19
PBR
+0.93%
$11.84
NIO
+0.73%
$6.89
IBIO
-8.63%
$1.27
CUTR
-10.19%
$0.09
KMI
-4.75%
$26.25
NVTS
+0.03%
$13.61
WLGS
-5.57%
$0.04
SOUN
+2.70%
$18.23
LUV
-6.25%
$31.65
RR
+7.11%
$5.42
TE
-9.73%
$3.71
ETWO
0.00%
$3.30
SCWO
+32.07%
$0.48
SNAP
+1.28%
$7.87
BAC
+1.29%
$51.76
RIVN
+1.31%
$13.09
BTE
+5.72%
$2.40
APLD
+9.01%
$33.38
DNUT
+1.98%
$4.11
HOOD
+5.58%
$134.33
LUMN
+10.65%
$7.79
VALE
-0.52%
$11.46
AFMD
-34.94%
$0.18
NCLH
-0.63%
$23.48
ERIC
-0.31%
$9.48
CLSK
+4.80%
$17.67
KDLY
+10.41%
$0.79
ELBM
+3.61%
$1.72
NAKA
+10.41%
$0.79
YYAI
-50.60%
$0.09
BYND
-20.67%
$2.84
SCNX
+354.94%
$2.60
YDKG
+5.58%
$0.07
F
-0.72%
$12.34
CGBS
-39.47%
$0.03
VHAI
0.00%
$0.00
RGTI
+9.80%
$39.59
AIRE
+38.18%
$0.98
RIG
+13.74%
$3.89
TSLA
+2.28%
$448.98
INTC
+3.35%
$38.15
BURU
-5.27%
$0.34
VTYX
+70.98%
$6.60
NOK
+11.17%
$6.17
QBTS
+13.81%
$31.06
NVDA
+1.04%
$182.16
T
-3.63%
$24.62
ADAP
-3.44%
$0.07
MSAI
+101.73%
$1.35
AAL
+5.62%
$12.77
BITF
+5.71%
$4.16
VIVK
+5.68%
$0.26
WTO
-7.04%
$0.06
IONZ
-14.59%
$3.98
AREB
+75.34%
$3.77
AXDX
-61.36%
$0.03
DNN
+0.36%
$2.73
IONQ
+7.06%
$59.37
PLUG
-1.36%
$2.88
ABEV
+0.45%
$2.21
SMCI
-8.72%
$47.92
QUBT
+7.19%
$15.94
TLRY
+2.06%
$1.48
VZ
-3.51%
$38.40
RGTZ
-20.27%
$14.90
GRAB
+1.77%
$5.72
SOFI
+3.27%
$28.08
RBNE
+7.87%
$1.37
BBD
+1.51%
$3.35
JOBY
+1.29%
$15.67
RF
-0.04%
$24.10
CAN
+3.22%
$1.76
ETHD
-3.17%
$3.97
ACHR
+0.46%
$10.91
QS
+7.95%
$14.66
RMBL
+60.50%
$3.21
SGBX
+29.82%
$2.96
AMD
+2.06%
$234.99
BTG
+0.38%
$5.23
ADD
-25.47%
$0.05
VLY
+4.24%
$10.56
ONDS
+4.74%
$7.06
GPUS
-0.28%
$0.38
PLTR
+2.84%
$180.48
LAES
+5.92%
$5.72
RXRX
-0.34%
$5.73
SRM
+53.27%
$10.30
CIFR
+7.10%
$17.25
PFE
-0.20%
$24.67
TNGX
-13.04%
$7.53
UUUU
-6.50%
$21.26
BTBT
+3.62%
$3.72
AAPL
+0.43%
$259.58
MARA
+0.36%
$19.22
AMC
-0.72%
$2.73
DVLT
+5.14%
$2.25
WBD
+3.50%
$21.25
AMZN
+1.44%
$221.09
IREN
+7.77%
$55.86
HPE
+0.43%
$23.19
PBR
+0.93%
$11.84
NIO
+0.73%
$6.89
IBIO
-8.63%
$1.27
CUTR
-10.19%
$0.09
KMI
-4.75%
$26.25
NVTS
+0.03%
$13.61
WLGS
-5.57%
$0.04
SOUN
+2.70%
$18.23
LUV
-6.25%
$31.65
RR
+7.11%
$5.42
TE
-9.73%
$3.71
ETWO
0.00%
$3.30
SCWO
+32.07%
$0.48
SNAP
+1.28%
$7.87
BAC
+1.29%
$51.76
RIVN
+1.31%
$13.09
BTE
+5.72%
$2.40
APLD
+9.01%
$33.38
DNUT
+1.98%
$4.11
HOOD
+5.58%
$134.33
LUMN
+10.65%
$7.79
VALE
-0.52%
$11.46
AFMD
-34.94%
$0.18
NCLH
-0.63%
$23.48
ERIC
-0.31%
$9.48
CLSK
+4.80%
$17.67
KDLY
+10.41%
$0.79
ELBM
+3.61%
$1.72
NAKA
+10.41%
$0.79
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.